Leading the way to innovative treatments for gastrointestinal diseases
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for acid-related gastrointestinal disorders. The company holds exclusive US, European, and Canadian rights to a potassium-competitive acid blocker (PCAB), a next-generation mechanism that offers an alternative to proton pump inhibitors for conditions such as erosive esophagitis and H. pylori infection.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2023
May 2022
Oct 2019
May 2019
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
